Invivyd Launches Phase 3 Trial to Compare COVID Antibody vs. mRNA Vaccine

Event summary

  • Invivyd dosed first participants in the LIBERTY Phase 3 trial on June 9, 2026, evaluating VYD2311 antibody vs. mRNA COVID vaccine.
  • Trial will enroll 210 adults aged 18-49, comparing safety, tolerability, and immunology of VYD2311 alone, mRNA vaccine alone, and co-administration.
  • Topline data expected in Q3 2026, alongside results from the DECLARATION pivotal trial.
  • VYD2311 is designed as a vaccine alternative with a potentially more tolerable profile than mRNA vaccines.

The big picture

Invivyd's LIBERTY trial is part of a broader push to establish monoclonal antibodies as a more tolerable alternative to mRNA vaccines for COVID-19 prevention. The study comes as vaccine hesitancy persists, driven by concerns over side effects, and as competitors like Sanofi highlight the systemic reactions associated with mRNA shots. If successful, VYD2311 could carve out a niche in prophylactic COVID care, particularly for vulnerable populations.

What we're watching

Regulatory Pathway
Whether LIBERTY data will support VYD2311's regulatory filings and approval prospects.
Market Differentiation
How Invivyd positions VYD2311 as a preferred alternative to mRNA vaccines in a post-pandemic market.
Clinical Execution
The pace at which Invivyd can enroll participants and report topline data from LIBERTY and DECLARATION trials.